Welcome to our dedicated page for Mind Medicine SEC filings (Ticker: MNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates for brain health disorders, and its filings offer detailed information on clinical progress, financing transactions and corporate matters.
Through Forms 8‑K, MindMed reports material events such as underwritten public offerings of common shares under its shelf registration statement on Form S‑3, entry into underwriting agreements, and the intended use of proceeds to fund research and development, working capital and general corporate purposes. Other 8‑K filings describe the release of quarterly financial results, updated corporate presentations, and announcements related to clinical and scientific milestones, including publication of MM120 trial data in generalized anxiety disorder.
MindMed’s filings also identify its jurisdiction of incorporation in British Columbia, Canada, its listing of common shares on The Nasdaq Stock Market LLC under the symbol MNMD, and its status as an emerging growth company. Investors can use this page to review prospectus supplements, opinions and exhibits referenced in 8‑K filings, as well as periodic reports such as Forms 10‑K and 10‑Q accessed via EDGAR.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, such as the terms of public offerings, changes in cash and investments, and updates on the development of MM120 and MM402. Real-time updates from EDGAR, along with structured access to Forms 10‑K, 10‑Q and 4, help users quickly locate information on MindMed’s financial condition, capital structure and insider-related disclosures.
Mind Medicine (MindMed) Inc. is offering 18,375,000 common shares at $12.25 per share in a primary follow‑on under its S‑3 shelf. The deal implies a gross offering size of $225,093,750, with underwriting discounts of $13,505,625 and estimated net proceeds of approximately $211.1 million after expenses. The company granted underwriters a 30‑day option for up to 2,756,250 additional shares.
MindMed expects to use proceeds for research and development of its pipeline, including MM120 for generalized anxiety disorder and major depressive disorder and MM402 for autism spectrum disorder, plus working capital and general corporate purposes. Shares outstanding will be 94,178,251 after the offering (or 96,934,501 if the option is fully exercised). As of September 30, 2025, cash, cash equivalents and investments were approximately $209.1 million.
The shares trade on Nasdaq as MNMD. Delivery is expected on or about October 31, 2025.
Mind Medicine (MindMed) Inc. disclosed preliminary liquidity. The company reported estimated unaudited cash, cash equivalents and investments of approximately $209.1 million as of September 30, 2025. This figure was included in a prospectus supplement and an updated corporate presentation posted on October 29, 2025.
Management emphasized that the estimate is preliminary and subject to completion, and that the company’s independent auditor, KPMG LLP, has not audited, reviewed, or compiled this information. The company noted that adjustments may be required once customary procedures are completed.
MindMed also filed the corporate presentation as Exhibit 99.1, making the materials available for investors seeking additional context on its financial position.
Mind Medicine (MindMed) Inc. filed a preliminary prospectus supplement for a primary offering of common shares and pre‑funded warrants, with joint bookrunners Jefferies, Leerink Partners and Evercore ISI. The company has also granted the underwriters a 30‑day option to purchase additional common shares. Net proceeds will go to research and development of product candidates and to working capital and general corporate purposes.
Pre‑funded warrants will be immediately exercisable until fully exercised and include ownership caps of 4.99% or 9.99% at the holder’s election, adjustable up to 19.99% with notice. MNMD trades on Nasdaq; the last reported price was $12.87 per share on October 28, 2025. Shares outstanding were 75,803,251 as of June 30, 2025; this is a baseline figure, not the amount being offered.
The company reported approximately $209.1 million in cash, cash equivalents and investments as of September 30, 2025. MindMed is advancing MM120 into Phase 3 for generalized anxiety disorder and major depressive disorder, and planning a Phase 2a study of MM402 in autism spectrum disorder.
Robert Barrow, Chief Executive Officer and director of Mind Medicine (MindMed) Inc. (MNMD), reported a sale of 25,797 common shares on 09/25/2025 at a price of $9.77 per share. The filing states the shares were sold to satisfy withholding tax obligations arising from the settlement of vested restricted stock units, executed under a Rule 10b5-1 plan adopted on June 15, 2022.
Following the transaction, Mr. Barrow beneficially owned 804,268 shares. The Form 4 was signed by an attorney-in-fact on 09/26/2025 and was filed as a single reporting person filing. The disclosure lists this as a routine sell-to-cover related to RSU vesting rather than an open-market discretionary sale.
Dan Karlin, Chief Medical Officer of Mind Medicine (MNMD), reported a transaction dated 09/25/2025 in which 7,704 common shares were disposed of at $9.77 per share. The filing states these shares were sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units under a Rule 10b5-1 plan adopted on June 14, 2022. After the reported disposition, the reporting person beneficially owns 430,625 common shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Karlin on 09/26/2025.
Mind Medicine (MNMD) Form 144 notice discloses a proposed sale of 11,278 common shares by an insider through Morgan Stanley Smith Barney, with an aggregate market value of $110,216.51. The filer indicates the shares were acquired on 09/25/2025 as restricted stock vesting under a registered plan and the intended method of payment is compensation. The sale is listed with an approximate sale date of 09/25/2025 on NASDAQ. The filing also reports a prior sale by Mark Sullivan of 11,491 shares on 06/25/2025 for $78,169.83. The notice includes the standard insider representation about lack of undisclosed material information.
Mind Medicine (MNMD) Form 144 shows an intended sale of 7,704 common shares by a person for whose account the securities were issued, through Morgan Stanley Smith Barney LLC on 09/25/2025 on NASDAQ. The filing reports an aggregate market value of $75,288.88 for the shares and lists 76,087,943 shares outstanding for the issuer. The shares to be sold were acquired the same day, 09/25/2025, as restricted stock vesting under a registered plan and payment is recorded as Not Applicable. The filing also discloses a prior sale by DANIEL ROLLINGS KARLIN of 7,848 shares on 06/25/2025 for gross proceeds of $53,387.59. The notice includes the required signature representation regarding absence of undisclosed material adverse information.
Form 144 notice for Mind Medicine (MNMD): The filing records a proposed sale of 25,797 common shares with an aggregate market value of $252,106.34 through Morgan Stanley Smith Barney LLC on 09/25/2025 on Nasdaq. The shares were acquired the same day as restricted stock vesting under a registered plan and payment is listed as Not Applicable. The form also discloses a prior sale by Robert B Barrow of 26,491 shares on 06/25/2025 for gross proceeds of $180,210.33. The filer attests there is no undisclosed material adverse information and the standard signature and legal warning language appear.
Mind Medicine (MindMed) Inc. filed a report stating that it has issued a press release about new clinical data. On September 4, 2025, the company announced the publication of results from its Phase 2b clinical trial of MM120 (Lysergide D-Tartrate) for Generalized Anxiety Disorder in the Journal of the American Medical Association. The related press release is included as an exhibit to provide more detail on the trial results and their context.